Shanghai – September 12, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) platform achieved sustained transfusion independence or elimination of vaso-occlusive crises (VOCs) in four new patients from Nigeria, Laos, Malaysia and Pakistan, extending clinical validation beyond the Chinese cohort where five patients previously achieved full transfusion independence.

Shanghai – September 12, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 delivered durable clinical remission in patients with sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) across four distinct genetic backgrounds, according to a peer-reviewed study published in Cell Stem Cell on September 7, 2026.

Shanghai – September 11, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 achieved full transfusion independence or elimination of vaso-occlusive crises (VOC) in four new patients from Nigeria, Laos, Malaysia and Pakistan, expanding on earlier results in five Chinese patients who all reached transfusion independence.